Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 521-529

  Lee, Philip E ^a,c,e   Gill, Sudeep S ^b,c   Rochon, Paula ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^e ST PAUL S HOSPITAL   (Canada)

Author keywords

Atypical antipsychotics; Dementia; Olanzapine; Risperidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTINDOLE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOLEPTIL; ZOTEPINE;

ANOREXIA; ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DEATH; DEMENTIA; DISEASE RESISTANCE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FALLING; GAIT DISORDER; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERSALIVATION; HYPOTENSION; INCIDENCE; LIPID METABOLISM; MENTAL DISEASE; META ANALYSIS; MOTOR DYSFUNCTION; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PERICARDIAL EFFUSION; PERICARDITIS; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STROKE; SUICIDAL BEHAVIOR; SYMPTOM; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; WEIGHT GAIN;

EID: 33847295244     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.521     Document Type: Review

References (77)

1. Aarsland D, Perry R, Larsen JP, et al. 2005. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry, 66:633-7.
2. Ballard C, Margallo-Lana M, Juszczak E, et al. 2005. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ, 330:874.
3. Ballard CG, Margallo-Lana ML. 2004. The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. J Clin Psychiatry, 65(Suppl 11):23-8.
4. Baskys A. 2004. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry, 65(Suppl 11):16-22.
5. Bhanushali MJ, Tuite PJ. 2004. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin, 22:389-411.
6. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. 2005. The quality of antipsychotic drug prescribing in nursing homes, Arch Intern Med, 165:1280-5.
7. Brodaty H, Ames D, Snowdon J, et al. 2003. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia, J Clin Psychiatry, 64:134-43.
8. Bronskill SE, Anderson GM, Sykora K, et al. 2004. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc, 52:749-55.
9. Byerly MJ, Weber MT, Brooks DL, et al. 2001. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging, 18:45-61.
10. Caroff SN, Mann SC, Keck PE Jr, 1998. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry, 44:378-81.
11. Cohen-Mansfield J. 1986. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc, 34:722-7.
12. Cohen-Mansfield J, Werner P, Marx MS. 1989. An observational study of agitation in agitated nursing home residents. Int Psychogeriatr, 1:153-65.
13. Cole SA, Saleem R, Shea WP, et al. 2005. Ziprasidone for agitation or psychosis in dementia: four cases. Int J Psychiatry Med, 35:91-8.
14. Committee on Safety of Medicines/Medicines Control Agency. 2001. QT interval prolongation with antipsychotics. 27, 4.
15. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology, 44:2308-14.
16. Davidson M, Harvey PD, Vervarcke J, et al. 2000. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry, 15:506-14.
17. De Deyn PP, Carrasco MM, Deberdt W, et al. 2004. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease, Int J Geriatr Psychiatry, 2:115-26.
18. De Deyn PP, Rabheru K, Rasmussen A, et al. 1999. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53:946-55.
19. De Deyn PP, Jeste DV, Swanink R, et al. 2005. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol, 25:463-7.
20. Duff, G, Committee on Safety of Medications - Atypical antipsychotic drugs and stroke. 2004.
21. Ellis T, Cudkowicz ME, Sexton PM, et al. 2000. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci, 12:364-9.
22. Etminan M, Streiner DL, Rochon PA. 2003. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy, 23:1411-5.
23. European Agency for the Evaluation of Medicinal Products (EMEA. Cerebrovascular events and increased mortality in eldery patients with dementia. 2004.
24. Fernandez HH, Friedman JH, Jacques C, et al. 1999. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord, 14:484-7.
25. Fernandez HH, Trieschmann ME, Friedman JH. 2004. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol, 27:4-5.
26. Fernandez HH, Wu CK, Ott BR. 2003. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother, 42027-37.
27. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. 2002. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry, 63:920-30.
28. Gill SS, Rochon PA, Herrmann N, et al. 2005. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ, 330:445.
29. Greco KE, Tune LE, Brown FW, et al. 2005. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. J Clin Psychiatry, 66:928-9.
30. Health Canada. Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia [online]. Accessed 7 April 2006. URL: http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/2005/2005_63_e.html.
31. Howanitz E, Pardo M, Smelson DA, et al. 1999. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry, 60:41-4. [erratum J Clin Psychiatry, 60:341].
32. Hughes CM, Lapane KL. 2005. Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been?. Drugs Aging, 22:339-51.
33. Hughes CM, Lapane KL, Mor V. 1999. Impact of legislation on nursing home care in the United States: lessons for the United Kingdom. BMJ, 319:1060-2.
34. Hwang TJ, Masterman DL, Ortiz F, et al. 2004 Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord, 18:17-21.
35. Ichikawa J, Ishii H, Bonaccorso S, et al. 2001. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem, 76:1521-31.
36. Ichikawa J, Meltzer HY. 1999. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci, 249(Suppl 8).
37. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. 2000. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry, 157:1150-5.
38. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. 1999. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry, 7:70-6.
39. Kapur, S. Seeman, P. 2001, Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry, 158, 3, pp. 360-369.
40. Katz IR, Jeste DV, Mintzer JE, et al. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry, 60:107-15.
41. Kirchner V, Kelly CA, Harvey RJ. 2000. Thioridazine for dementia.[update in Cochrane Database Syst Rev. 2001;(3):CD000464; PMID: 11686961]. Cochrane Database of Systematic Reviews(2):CD000464.
42. Klein C, Gordon J, Pollak L, et al. 2003. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol, 26:8-11.
43. Koro CE, Fedder DO, L'Italien G, et al. 2002 An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry, 59:1021-6.
44. Koro CE, Meyer JM. 2005. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol, 6:148-57.
45. Lanctot KL, Best TS, Mittmann N, et al. 1998. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry, 59:550-61.
46. Lee PE, Gill SS, Freedman M, et al. 2004. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ, 329(7457):75.
47. Lee PE, Sykora K, Gill SS, et al. 2005. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc, 53:1374-9.
48. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353:1209-23.
49. Livingston G, Johnston K, Katona C, et al. Old Age Task Force of the World Federation of Biological Psychiatry. 2005. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry, 162:1996-2021.
50. Llorente MD, Olsen EJ, Leyva O, et al. 1998. Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. J Am Geriatr Soc, 46:198-201.
51. Madhusoodanan S, Brenner R, Suresh P, et al. 2000. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry, 12:11-18.
52. Meltzer HY. 1992. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry-Supplementum, 17:22-9.
53. Meltzer HY, Matsubara S, Lee JC. 1989. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther, 251:238-46.
54. Morikawa M, Kishimoto T. 2002. Probable dementia with Lewy bodies and risperidone-induced delirium. Can J Psychiatry, 47:976.
55. Mortimer JA, Ebbitt B, Jun SP, et al. 1992. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology, 42:1689-96.
56. National Institute of Mental Health. Clinical Global Impressions; Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Revised. Bethesda, MD, US: Department of Health, Education, and Welfare. p217-22
57. Pollak P, Tison F, Rascol O, et al. 2004. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry, 75:689-95.
58. Reisberg B, Borenstein J, Salob SP, et al. 1987. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry, 48(Suppl 15).
59. Rinaldi P, Spazzafumo L, Mastriforti R, et al. Study Group on Brain Aging of the Italian Society of Gerontology and Geriatrics. 2005. Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study. Int J Geriatr Psychiatry, 201:68-174.
60. Rochon PA, Stukel TA, Sykora K, et al. 2005, Atypical antipsychotics and parkinsonism, Arch Intern Med, 165:1882-8.
61. Sadek J, Rockwood K. 2003. Coma with accidental single dose of an atypical neuroleptic in a patient with Lewy Body dementia. Am J Geriatr Psychiatry, 11:112-3.
62. Sajatovic M, Jaskiw G, Konicki PE, et al. 1997. Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry, 12:553-8.
63. Sajatovic M, Ramirez LF, Belton J, et al. 1999. Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness. Compr Psychiatry, 40:198-202.
64. Saxton J, Swihart AA. 1989. Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med, 5:531-43.
65. Schneider LS, Dagerman KS, Insel P. 2005a. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294:1934-43.
66. Schneider LS, Pollock VE, Lyness SA. 1990. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc, 38:553-63.
67. Schneider LS, Dagerman KS, Insel P. 2005b. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 294:1934-43.
68. Shoff RI, Fought RL, Ray WA. 1994. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA, 271:358-62.
69. Sink KM, Covinsky KE, Newcomer R, et al. 2004. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J Am Geriatr Soc, 52:1277-83.
70. Sink KM, Holden KF, Yaffe K. 2005. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA, 293:596-608.
71. Steele C, Rovner B, Chase GA, et al. 1990. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease Am J Psychiatry, 147:1049-51.
72. Steinberg M, Tschanz JT, Corcoran C, et al. 2004. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry, 19:19-26.
73. Strange PG. 2001. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev, 53:119-33.
74. Street JS, Clark WS, Gannon KS, et al. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry, 57:968-76.
75. Thakore JH. 2005. Metabolic syndrome and schizophrenia, Br J Psychiatry, 186:455-56.
76. United States FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances [online]. Accessed 7 April 2006. URL: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm.
77. Yaffe K, Fox P, Newcomer R, et al. 2002. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA, 287:2090-7.